What is William Blair’s Estimate for Exagen FY2024 Earnings?

Exagen Inc. (NASDAQ:XGN) – William Blair boosted their FY2024 EPS estimates for shares of Exagen in a report released on Wednesday, November 13th. William Blair analyst A. Brackmann now expects that the company will post earnings of ($0.89) per share for the year, up from their prior forecast of ($0.94). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.87) per share. William Blair also issued estimates for Exagen’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.70) EPS.

Exagen Stock Performance

XGN opened at $3.53 on Monday. The business has a 50 day moving average price of $2.83 and a two-hundred day moving average price of $2.43. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The company has a market capitalization of $62.26 million, a price-to-earnings ratio of -3.76 and a beta of 1.35. Exagen has a 1-year low of $1.30 and a 1-year high of $3.71.

Exagen (NASDAQ:XGN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The firm had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $13.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same period last year, the firm earned ($0.31) EPS.

Hedge Funds Weigh In On Exagen

Hedge funds have recently modified their holdings of the stock. Verus Capital Partners LLC acquired a new position in shares of Exagen in the 3rd quarter valued at $39,000. Creative Planning purchased a new position in shares of Exagen in the third quarter worth approximately $110,000. Renaissance Technologies LLC raised its holdings in shares of Exagen by 93.3% during the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock valued at $172,000 after acquiring an additional 45,476 shares during the period. Palumbo Wealth Management LLC lifted its holdings in shares of Exagen by 14.5% in the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock valued at $236,000 after purchasing an additional 9,695 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its stake in Exagen by 49.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after acquiring an additional 175,701 shares in the last quarter. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exagen

In related news, CEO John Aballi purchased 24,305 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were bought at an average price of $2.81 per share, with a total value of $68,297.05. Following the completion of the acquisition, the chief executive officer now owns 689,799 shares of the company’s stock, valued at approximately $1,938,335.19. This represents a 3.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 26.10% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).